Axio Biosolutions creates Advisory Board including faculty members from Harvard, Stanford

Bengaluru: Med-tech startup, Axio Biosolutions, is all set to step up its US launch plans with the announcement of its top-notch Scientific Advisory Board. As the first-ever Indian company to get USFDA clearance for a haemostat, Axio is well poised to disrupt the wound care industry globally.

The Bengaluru-based enterprise has appointed Dr Shiladitya Sengupta, Assistant Professor of Medicine at Harvard Medical School, as Chairman, and Dr S V Mahadevan, Professor of Emergency Medicine at Stanford University, as a member of its Scientific Advisory Board.

An alumnus of the All India Institute of Medical Sciences, where he received the Geeta Mital Gold Medal, Dr Sengupta serves as Assistant Professor of Health Sciences and Technology at MIT, and principal investigator at the Dana- Farber Cancer Institute, Boston. After completing his PhD at Trinity College, University of Cambridge (where he was a Nehru Scholar as well as a British Chevening Scholar) and a fellowship in Biological Engineering from MIT, Dr Sengupta joined the Harvard faculty.

The co-founder of Akamara Therapeutics (hitherto Invictus Oncology), Vyome Biosciences, Mitra Biotech and Cerulean Pharma Inc. (served on the Scientific Advisory Board), Dr Sengupta, has also co-chaired the Center for Regenerative Medicine at the Brigham and Women’s Hospital in Boston. He has been the recipient of several prestigious awards, including the TR35 Innovator Award by MIT Technology Review magazine; the Era of Hope Scholar Award and the Innovator Collaborative Award from the US Department of Defense; the Coulter Foundation Career Award; and the Shakuntala Amir Chand Award from the Indian Council for Medical Research.

Axio’s other notable appointment, Dr S V Mahadevan, Professor of Emergency Medicine at Stanford University, Palo Alto, California, brings critical expertise of over 23 years in emergency medicine to the Scientific Advisory Board. The founding chair of the Department of Emergency Medicine at Stanford (2015-17) and founding Director of Stanford Emergency Medicine International (2000-2015), Dr Mahadevan currently serves as both the Director of Global Affairs and Strategy for Stanford Medicine as well as the Director of South Asia Outreach, Center for Asian Health Research and Education (CARE).

Dr Mahadevan has received numerous esteemed teaching awards throughout his illustrious career and is the lead editor of the textbook, An Introduction to Clinical Emergency Medicine, which won the 2006 American Medical Writer’s Association Award in the Physician’s Category. Currently, he is a teaching physician at Stanford Health Care.

Commenting on the appointments, Leo Mavely, CEO of Axio Biosolutions, said, “While Dr Sengupta is a serial entrepreneur and inventor of over 350 pending/granted patents, with more than 100 papers published in scientific journals, Dr Mahadevan’s expertise in emergency medicine is unparalleled. We hope to leverage the rich expertise of our Scientific Advisory Board to support Axio’s vision of building Indian innovation in wound care and surgical care for the world market.”

The startup caters to the Indian Armed Forces, BSF, NSG, paramilitary forces, hospitals and emergency services not only in India, but across the globe, and claims that its home-grown first aid solution has prevented "countless deaths due to haemorrhage and grievous injuries."

Also Read: Axio Biosolutions raises Rs 47 crore from Ratan Tata, others